Literature DB >> 25564638

Resolution of NASH with weight loss documented by hepatic MRI.

Vasvi Singh1, Saurav Luthra1, Tarec K Elajami2, Francine K Welty2.   

Abstract

A 57-year-old Asian woman with type 2 diabetes mellitus, hypertension, obesity, dyslipidaemia and history of breast cancer, was referred to the cardiovascular health and lipid centre for evaluation and management of dyslipidaemia and NASH (Non-alcoholic steatohepatitis) in 2010. She originally had a detailed work up at the liver clinic for elevated liver enzymes, with no associated symptoms. Initial hepatic MRI on 22 January 2007 showed diffuse fatty infiltration quantitated at 15%. We counselled her on lifestyle modifications, including dietary measures and exercise, geared toward weight loss. Over the next 2 years, she lost 24.5 lbs; repeat hepatic MRI on 22 December 2011 showed 6% hepatic fat, which is within the normal range. This case demonstrates the efficacy of significant weight loss in the improvement and resolution of NASH. We believe that this is the first case report documenting this through liver MRI. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25564638      PMCID: PMC4289812          DOI: 10.1136/bcr-2014-207107

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

2.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

Authors:  T Ueno; H Sugawara; K Sujaku; O Hashimoto; R Tsuji; S Tamaki; T Torimura; S Inuzuka; M Sata; K Tanikawa
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

3.  Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects.

Authors:  D Enette Larson-Meyer; Leonie K Heilbronn; Leanne M Redman; Bradley R Newcomer; Madlyn I Frisard; Steve Anton; Steven R Smith; Anthony Alfonso; Eric Ravussin
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

Authors:  H Knobler; A Schattner; T Zhornicki; S D Malnick; D Keter; N Sokolovskaya; Y Lurie; D D Bass
Journal:  QJM       Date:  1999-02

6.  MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging.

Authors:  Jorge Elias; Ersan Altun; Steven Zacks; Diane M Armao; John T Woosley; Richard C Semelka
Journal:  Magn Reson Imaging       Date:  2009-04-07       Impact factor: 2.546

7.  Effect of onsite dietitian counseling on weight loss and lipid levels in an outpatient physician office.

Authors:  Francine K Welty; Melita M Nasca; Natalie S Lew; Sue Gregoire; Yuheng Ruan
Journal:  Am J Cardiol       Date:  2007-05-11       Impact factor: 2.778

8.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; David E Kleiner; Heather M Niemeier; Elizabeth Jackvony; Marie Kearns; Jack R Wands; Joseph L Fava; Rena R Wing
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

9.  Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

Authors:  John B Dixon; Prithi S Bhathal; Norman R Hughes; Paul E O'Brien
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

10.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.